Background
Pfizer held a family of patents covering atorvastatin — the active ingredient in Lipitor, one of the world’s bestselling prescription drugs used to treat high cholesterol. Among these was a patent with claims directed to various forms of atorvastatin, including atorvastatin acid, atorvastatin lactone, and their pharmaceutically acceptable salts. Pfizer asserted that Ranbaxy’s generic atorvastatin product, filed through the Hatch-Waxman ANDA process, infringed the sole claim that the district court found Ranbaxy’s ANDA product would infringe — claim 6.
Claim 6 was a dependent claim that recited “the hemicalcium salt of the compound of claim 2.” Claim 2, in turn, was dependent on claim 1 and specifically recited atorvastatin acid only — not the pharmaceutically acceptable salts. Ranbaxy argued that claim 6 was therefore invalid under 35 U.S.C. § 112, paragraph 4, because it attempted to depend from (and add limitations to) claim 2, but the hemicalcium salt of atorvastatin is not within the scope of claim 2 (which covers only the acid form, not salts).
The central question was whether a dependent claim that claims subject matter not encompassed within the independent claim it purports to depend from is invalid under § 112, ¶ 4.
The Court’s Holding
The Federal Circuit reversed the district court and held claim 6 invalid. Writing for the court, Judge Dyk held that 35 U.S.C. § 112, paragraph 4 requires that a dependent claim “incorporate by reference all the limitations of the claim to which it refers” and then “specify a further limitation of the subject matter claimed.” The operative word is “further” — the dependent claim must narrow the independent claim, not depart from it into different subject matter.
Because claim 2 covered only atorvastatin acid (not salts), claim 6’s hemicalcium salt was outside the scope of claim 2 entirely. Claim 6 did not add a further limitation to claim 2 — it claimed something that claim 2 did not cover at all. This violated § 112, ¶ 4’s requirement that a dependent claim must refer to a claim that actually encompasses the dependent claim’s subject matter.
The Federal Circuit affirmed the remaining holdings: the claim construction of claim 1, and the validity of the patent term extension under the Hatch-Waxman Act. But because claim 6 was the only claim that the lower court found would be infringed by Ranbaxy’s product, its invalidity effectively ended Pfizer’s infringement case against Ranbaxy on those patents.
Key Takeaways
- A dependent claim must “further limit” the independent claim it depends from — it cannot claim subject matter that falls outside the scope of the parent claim.
- If a dependent claim’s subject matter is not included within the independent claim, the dependent claim is invalid under 35 U.S.C. § 112, paragraph 4.
- Patent drafters must ensure that each dependent claim’s subject matter is a subset of the claim it depends from — not a parallel or alternative subject matter.
- Even small claim drafting errors can have massive commercial consequences in high-value pharmaceutical patent litigation.
- Pfizer lost its main infringement claim against Ranbaxy’s generic Lipitor product as a result of this drafting defect.
Why It Matters
Pfizer v. Ranbaxy is a cautionary tale about claim drafting precision. Lipitor was generating billions of dollars annually in sales, and Pfizer’s patent protection was partly undone not by a challenge to inventive step or prior art, but by a technical flaw in how one claim was written. The lesson is stark: a dependent claim that strays outside the scope of its parent claim is not merely poorly drafted — it is invalid.
The case reinforced the importance of rigorous claim chain review during patent prosecution and maintenance. It is frequently cited in patent practice guides as an example of the consequences of dependent-claim scope errors, and it remains relevant whenever companies attempt to use dependent claims to capture specific formulations (like particular salts or esters) that may not be fully encompassed by the independent claim’s scope.